Diabetologia

Papers
(The H4-Index of Diabetologia is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Up Front779
In Memoriam Werner Waldhäusl, 27 September 1937–22 May 2025508
The SWI/SNF chromatin remodelling complex regulates pancreatic endocrine cell expansion and differentiation in mice in vivo213
Critical comments regarding the assessment of quality of life and the clinical impact of the POWER2DM intervention. Reply to Pouwer F, Deschênes SS [letter]210
60th EASD Annual Meeting of the European Association for the Study of Diabetes196
Methodological considerations for interpreting long-term statin use and diabetes incidence148
Determination of autoantibodies in type 2 diabetes: one simple way to improve classification147
Differences in biopsy-proven diabetic kidney disease in individuals from Polynesia vs mainland France: a retrospective cohort study140
Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative129
Impact of normoglycaemia and prediabetes definitions on the estimated benefits of regression from prediabetes to normoglycaemia for type 2 diabetes risk114
Cardiovascular risk management among individuals with type 2 diabetes and severe mental illness: a cohort study101
58th EASD Annual Meeting of the European Association for the Study of Diabetes101
Branding foods as ‘healthy’ or ‘unhealthy’ based on marginal data calls findings into question. Reply to Kanter M [letter]99
Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes98
Scientists and scientific journals should adhere to ethical standards for the use and reporting of data from Indigenous people96
TBC1D30 regulates proinsulin and insulin secretion and is the target of a genomic association signal for proinsulin94
Inter- and intra-physician variability in insulin injection adjustments compared with Bayesian algorithm recommendations in type 1 diabetes94
Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study93
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials92
The impact of automated insulin delivery on glucose management in people with diabetes and advanced chronic kidney disease86
Paediatric diabetes subtypes in a consanguineous population: a single-centre cohort study from Kurdistan, Iraq83
Loneliness increases the risk of type 2 diabetes: a 20 year follow-up – results from the HUNT study81
Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy79
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes76
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care76
Sex-dependent intra-islet structural rearrangements affecting alpha-to-beta cell interactions lead to adaptive enhancements of Ca2+ dynamics in prediabetic beta cells76
The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT)76
Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory74
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection74
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities73
Embracing complexity: making sense of diet, nutrition, obesity and type 2 diabetes72
Ageing well with diabetes: the role of technology71
Repeated faecal microbiota transplantation for individuals with type 1 diabetes and gastroenteropathy70
Heterotypic macrophages/microglia differentially contribute to retinal ischaemia and neovascularisation70
GLP-1 receptor agonists in lean diabetes in racial and ethnic minority groups: closing the treatment gap69
Racial/ethnic and socioeconomic disparities in achievement of treatment goals within a clinical trial: a secondary analysis of the ACCORD trial69
eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes69
A simple score-based strategy to improve equity of the UK biennial diabetic eye screening protocol among people deemed as low risk66
Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open64
Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulations64
Up Front63
Daniel Porte Jr, 13 August 1931–13 May 202360
Mortality risk for kidney transplant candidates with diabetes: a population cohort study57
Adverse pregnancy outcomes in women with type 1 diabetes are associated with multiple alterations in the vaginal microbiome57
Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis56
Frequency and clinical characteristics of children and young people with type 2 diabetes at diagnosis from five world regions between 2012 and 2021: data from the SWEET Registry55
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes54
Reassessing the evidence: prandial state dictates glycaemic responses to exercise in individuals with type 1 diabetes to a greater extent than intensity54
Pinpointing precision medicine for diabetes mellitus53
Perspectives on human adipose tissue: from cellular mechanisms to clinical complications53
Targeted proteomics identifies potential biomarkers of dysglycaemia, beta cell function and insulin sensitivity in Black African men and women52
Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study51
0.08714485168457